Cargando…

Comparison of Compliance and Efficacy of Pegylated Interferon α-2a and α-2b in Adults with Chronic Hepatitis C

This study compares treatment completion rates and outcomes in hepatitis C virus (HCV) patients between those aged <60 and ≥60 years receiving pegylated interferon (PEG-IFN) α-2a or α-2b combined with ribavirin. No significant differences were found in treatment completion rates and virological r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Jing-Hong, Chang, Ming-Ling, Huang, Tung-Jung, Yeh, Chau-Ting, Chiu, Wen-Nan, Chiang, Ming-Shih, Chen, Mei-Yen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2019
Materias:	Research Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479237/ https://www.ncbi.nlm.nih.gov/pubmed/30855203 http://dx.doi.org/10.1089/jir.2018.0028

Ejemplares similares

Tolerability and efficacy of pegylated consensus interferon-α in the treatment of chronic hepatitis C
por: Ding, Yan-Hua, et al.
Publicado: (2017)

Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon α-2a and Ribavirin for Chronic Hepatitis C
por: Rathi, Chetan, et al.
Publicado: (2015)

Efficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis
por: Coppola, Nicola, et al.
Publicado: (2012)

Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Concurrent Autoimmune Hepatitis and Grave's Disease in Hepatitis C during Pegylated Interferon α-2a and Ribavirin Therapy
por: Trikudanathan, Guru V., et al.
Publicado: (2011)

Analysis of the Efficacy and Safety of PEGylated Interferon-α2b Treatment in Inactive Hepatitis B Surface Antigen Carriers
por: Huang, Yan, et al.
Publicado: (2021)

Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience
por: Bahcecioglu, Ibrahim Halil, et al.
Publicado: (2015)

Cutaneous side effects of combination therapy of pegylated interferon 2α and ribavirin
por: Raducan, Anca, et al.
Publicado: (2014)

Adverse Skin Reactions due to Ribavirin in Hepatitis C Combination Therapy with Pegylated Interferon-α(2a)
por: Shindo, Masahisa, et al.
Publicado: (2013)

Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance
por: Pennisi, Manuela, et al.
Publicado: (2017)

Long-term Pegylated Interferon-α-2a Treatment for Chronic Hepatitis C in an Elderly Renal Transplant Recipient: Case Report and Literature Review
por: Zheng, Ming-Hua, et al.
Publicado: (2015)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
por: Chopra, Amit, et al.
Publicado: (2015)

Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy
por: Refaat, Bassem, et al.
Publicado: (2015)

Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme
por: Groves, M D, et al.
Publicado: (2009)

Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus
por: Tamai, Hideyuki, et al.
Publicado: (2016)

Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B
por: Su, Qian, et al.
Publicado: (2018)

Long-term pegylated interferon-α and its potential in the treatment of melanoma
por: Dummer, Reinhard, et al.
Publicado: (2009)

Effect of pegylated interferon-α2b add-on therapy on renal function in chronic hepatitis B patients: A real-world experience
por: Peng, Mei-Juan, et al.
Publicado: (2022)

Case Report: Severe Interstitial Pneumonitis Secondary to Pegylated Interferon α-2b and Ribavirin Treatment of Hepatitis C Infection
por: Fuhrmann, Valentin, et al.
Publicado: (2004)

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B
por: Huang, Yi-Wen, et al.
Publicado: (2020)

Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy
por: Turker, Kamuran, et al.
Publicado: (2015)

Therapeutic effects of pegylated-interferon-α2a in a mouse model of multiple sclerosis
por: Afraei, Sanaz, et al.
Publicado: (2018)

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis
por: Huang, Yi-Wen, et al.
Publicado: (2022)

Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients
por: He, Li-Ting, et al.
Publicado: (2016)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon‐α treatment in HBeAg‐positive chronic hepatitis B patients
por: Zhu, Ming‐Yu, et al.
Publicado: (2018)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
por: Akram, Madiha, et al.
Publicado: (2011)

Pegylated interferon α enhances recovery of memory T cells in e antigen positive chronic hepatitis B patients
por: Liu, Yong Zhe, et al.
Publicado: (2012)

Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C
por: Lim, Jae Hee, et al.
Publicado: (2011)

Clearance of HCV by Combination Therapy of Pegylated Interferon α-2a and Ribavirin Improves Insulin Resistance
por: Kim, Hong Joo, et al.
Publicado: (2009)

Pegylated Interferon-α2a Inhibits Proliferation of Human Liver Cancer Cells In Vitro and In Vivo
por: Kusano, Hironori, et al.
Publicado: (2013)

A Frail Hairy Cell Leukemia Patient Successfully Treated with Pegylated Interferon-α-2A
por: De Novellis, Danilo, et al.
Publicado: (2022)

Effects of gender and age on prevalence of cholelithiasis in patients with chronic HCV infection: A community-based cross-sectional study in an HCV-hyperendemic area
por: Hu, Jing-Hong, et al.
Publicado: (2018)

Type 1 Diabetes Caused by Interferon α-2α in Polycythemia Vera Therapy
por: Wang, Xian-Ling, et al.
Publicado: (2010)

Interferon α-inducible protein 27 is an oncogene and highly expressed in cholangiocarcinoma patients with poor survival
por: Chiang, Kun-Chun, et al.
Publicado: (2019)

Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study
por: Hsieh, Ming-Han, et al.
Publicado: (2022)

Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype
por: Guo, Xiaoyan, et al.
Publicado: (2012)

Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection
por: Ismail, Mona H.
Publicado: (2013)

Pretreatment microRNA levels can predict HBsAg clearance in CHB patients treated with pegylated interferon α-2a
por: Yang, Yanlin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7sb83ub89odsbtrqj0ankknsn7